These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31126889)

  • 21. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
    Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
    JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
    Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
    Yang L; Zhang Y; Shan W; Hu Z; Yuan J; Pi J; Wang Y; Fan L; Tang Z; Li C; Hu X; Tanyi JL; Fan Y; Huang Q; Montone K; Dang CV; Zhang L
    Sci Transl Med; 2017 Jul; 9(400):. PubMed ID: 28747513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
    Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
    Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation.
    Long X; Dai A; Huang T; Niu W; Liu L; Xu H; Yin T; Jiang T; Sun S; Lei P; Li C; Zhu X; Zhao J
    ACS Nano; 2023 Jul; 17(13):12915-12932. PubMed ID: 37352467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
    Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells.
    Garcia PL; Miller AL; Zeng L; van Waardenburg RCAM; Yang ES; Yoon KJ
    Front Oncol; 2022; 12():925718. PubMed ID: 35795040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.